<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05011266</url>
  </required_header>
  <id_info>
    <org_study_id>8171</org_study_id>
    <secondary_id>U01DA046430</secondary_id>
    <nct_id>NCT05011266</nct_id>
  </id_info>
  <brief_title>Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder</brief_title>
  <acronym>COMBO</acronym>
  <official_title>Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of a new pharmacological approach to increase&#xD;
      efficacy of treatment with extended release naltrexone (XR-naltrexone) for individuals with&#xD;
      opioid use disorder by combining it with buprenorphine-naloxone. This is a two arm,&#xD;
      double-blind, placebo-controlled study to examine whether addition of buprenorphine-naloxone&#xD;
      will improve treatment retention, reduce opioid craving, and improve mood over 24 weeks of&#xD;
      treatment with extended release naltrexone (XR-naltrexone) administered every four weeks for&#xD;
      a total of 6 injections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the effectiveness of a new pharmacological approach to increase&#xD;
      efficacy of treatment with extended release naltrexone (XR-naltrexone) for individuals with&#xD;
      opioid use disorder by combining it with buprenorphine-naloxone. Adding&#xD;
      buprenorphine-naloxone after the patient initiated XR-naltrexone will not produce mu opioid&#xD;
      agonist effect but kappa antagonist effects of buprenorphine may provide additional relief of&#xD;
      protracted withdrawal, craving, and mood disturbances persisting in patients treated with&#xD;
      XR-naltrexone and possibly contributing to premature treatment discontinuation and relapse.&#xD;
      This is a parallel arm, double-blind, placebo-controlled study to examine whether addition of&#xD;
      buprenorphine will improve treatment retention, reduce opioid craving, and improve mood over&#xD;
      24 weeks of treatment with XR-naltrexone administered every four weeks. Individuals with&#xD;
      Opioid Use Disorder (OUD) and beginning treatment with XR-naltrexone for maintenance&#xD;
      treatment will be randomized to treatment with adjunctive buprenorphine-naloxone or placebo&#xD;
      with 5 additional doses of XR-naltrexone, given every four weeks, and weekly medication&#xD;
      management. The study will provide detoxification and a first XR-Naltrexone injection if a&#xD;
      participant consents before the first XR-naltrexone injection. In all participants&#xD;
      randomization will occur after first XR-NTX injection. Buprenorphine-naloxone (sub-lingual&#xD;
      (SL), 4/1 mg/day) or placebo will be started after a first XR-naltrexone dose and tapered off&#xD;
      at study completion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2022</start_date>
  <completion_date type="Anticipated">June 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2026</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>parallel arm, double-blind, placebo-controlled buprenorphine compared to placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blind masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants receiving XR-naltrexone</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of participants receiving all six XR-naltrexone injections</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Opioid-use Disorder</condition>
  <arm_group>
    <arm_group_label>Buprenorphine-naloxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine/naloxone 4/1 mg/day sub-lingual tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo sub-lingual tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine/naloxone</intervention_name>
    <description>4 mg buprenorphine/1 mg naloxone daily</description>
    <arm_group_label>Buprenorphine-naloxone</arm_group_label>
    <other_name>Buprenorphine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo sub-lingual tablet daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals between the ages of 18-65 (inclusive) interested in antagonist-based&#xD;
             relapse prevention treatment&#xD;
&#xD;
          -  Meets current DSM-5 criteria for current opioid use disorder of at least six months&#xD;
             duration supported by urine toxicology positive for opioids OR naloxone challenge if&#xD;
             seeking detoxification and XR-NTX induction OR confirmed recent detoxification&#xD;
             treatment for opioids.&#xD;
&#xD;
          -  In otherwise good health based on complete medical history, physical examination,&#xD;
             vital signs measurement, ECG, and laboratory tests (hematology, blood chemistry,&#xD;
             urinalysis) within normal ranges.&#xD;
&#xD;
          -  Participants with active opioid use and those who recently completed detoxification&#xD;
             and received XR-NTX are eligible for the study. Participants may be enrolled before&#xD;
             initial XR-NTX injection or up to 2 weeks following an initial XR-NTX injection given&#xD;
             in any outside research or community-based treatment setting (inpatient, outpatient&#xD;
             residential). However, participants who had 30 or more opioid-free days prior to&#xD;
             consent will not be eligible for study inclusion.&#xD;
&#xD;
          -  Voluntarily seeking treatment for opioid use disorder.&#xD;
&#xD;
          -  Able to give written informed consent to participate in the study and showing a&#xD;
             thorough understanding of the difference between agonist and antagonist-based&#xD;
             treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Methadone maintenance or any use of illicit methadone in the week prior to XR-NTX&#xD;
             induction.&#xD;
&#xD;
          -  Maintenance on buprenorphine or frequent buprenorphine use in the week prior to XR-NTX&#xD;
             induction (must be using no more than 8 mg of buprenorphine per day and no more than 3&#xD;
             days per week).&#xD;
&#xD;
          -  Active medical illness which might make participation hazardous, such as untreated&#xD;
             hypertension, acute hepatitis with AST/ALT&gt; 3 times normal, AIDS (CD4 count under 200&#xD;
             or medically ill), unstable diabetes or unstable heart disease.&#xD;
&#xD;
          -  Active psychiatric disorder which might interfere with participation or make&#xD;
             participation hazardous, including DSM-5 Schizophrenia or any psychotic disorder,&#xD;
             severe Major Depressive Disorder, chronic Neurocognitive Disorder, or suicide risk or&#xD;
             1 or more suicide attempts within the past year&#xD;
&#xD;
          -  Pregnancy, lactation, or a plan of becoming pregnant. Women need to have negative&#xD;
             blood pregnancy test at screening and agree to practice dual contraceptives.&#xD;
&#xD;
          -  Physiological dependence on alcohol or sedative-hypnotics with impending withdrawal.&#xD;
             Other substance use diagnoses are not exclusionary.&#xD;
&#xD;
          -  History of allergic or adverse reaction to buprenorphine, naltrexone, naloxone,&#xD;
             clonidine, or clonazepam.&#xD;
&#xD;
          -  History of accidental drug overdose in the prior 6 months defined as an episode of&#xD;
             opioid-induced unconsciousness, whether or not medical treatment was sought or&#xD;
             received.&#xD;
&#xD;
          -  Painful medical condition that requires ongoing opioid analgesia or anticipated&#xD;
             surgery necessitating opioid medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Bisaga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adam Bisaga, md</last_name>
    <phone>646-774-6155</phone>
    <email>amb107@columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matisyahu Shulman, MD</last_name>
    <email>matisyahu.shulman@nyspi.columbia.edu</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Adam Bisaga</investigator_full_name>
    <investigator_title>Psuchiatrist</investigator_title>
  </responsible_party>
  <keyword>opioid use disorder</keyword>
  <keyword>treatment</keyword>
  <keyword>buprenorphine</keyword>
  <keyword>extended release naltrexone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results published in this report (after de-identification) (text, tables, figures)</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>beginning twelve months and ending 5 years after article publication</ipd_time_frame>
    <ipd_access_criteria>to researcher who provides a methodologically sound proposal to achieve aims in approved proposal</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

